Inicio › Cáncer de seno › Illinois
Ensayos clínicos de Cáncer de seno en Illinois
81 estudios sobre Cáncer de seno buscan participantes en Illinois.
Ciudades en Illinois
- Chicago59 estudios
- Evanston13 estudios
- Waukegan12 estudios
- Champaign11 estudios
- Naperville10 estudios
- Cicero10 estudios
- Springfield8 estudios
- Peoria8 estudios
- Decatur8 estudios
- Aurora7 estudios
- Carbondale7 estudios
- Arlington Heights6 estudios
- North Peoria5 estudios
- Elgin5 estudios
- Danville5 estudios
- Galesburg5 estudios
- Rockford5 estudios
- Charleston5 estudios
- Joliet5 estudios
- Bloomington5 estudios
Texto oficial del estudio (inglés)
A Trial to Evaluate Ovarian Suppression Following Subcutaneous ZOLADEX 10.8 mg in Premenopausal Women With Early-stage and Advanced HR+ Breast Cancer
- University of Illinois at Chicago, Chicago
- NorthShore University Health System - Evanston Hospital, Evanston
- Duly Health and Care, Lisle
- y 2 más
ReclutandoFase 1
Edades de 18 a 55 · Mujeres · Actualizado el 12 nov 2026 · NCT07310420Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)
- Orchard Healthcare Research Inc. ( Site 0006), Skokie
ReclutandoFase 2
Edades de 18 en adelante · Todos los sexos · Actualizado el 12 nov 2026 · NCT06797635S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity
- John H Stroger Jr Hospital of Cook County, Chicago
- Decatur Memorial Hospital, Decatur
- Loyola University Medical Center, Maywood
- y 1 más
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 12 nov 2026 · NCT03418961A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast Cancer
- University of Illinois Hospital & Health Sciences System, Chicago
ReclutandoFase 1/2
Edades de 18 en adelante · Todos los sexos · Actualizado el 10 nov 2026 · NCT06827236A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
- Southern Illinois Hospital Services ( Site 9554), Carterville
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 10 nov 2026 · NCT06966700ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer
- City of Hope Chicago, Zion
ReclutandoFase 2
Edades de 18 en adelante · Todos los sexos · Actualizado el 9 nov 2026 · NCT07007559BRE-04: Window of Opportunity Trial of Preoperative Low Dose Azacitidine in High-Risk Early Stage Breast Cancer
- University of Illinois Cancer Center, Chicago
ReclutandoFase 2
Edades de 18 en adelante · Todos los sexos · Actualizado el 6 nov 2026 · NCT04891068Abemaciclib Dose Escalation to Maintain Intensity (ADE-MI)
- University of Illinois, Chicago
ReclutandoFase 4
Edades de 18 en adelante · Todos los sexos · Actualizado el 6 nov 2026 · NCT06169371A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer
- City of Hope® Cancer Center Chicago, Zion
ReclutandoFase 1/2
Edades de 18 en adelante · Todos los sexos · Actualizado el 6 nov 2026 · NCT03424005Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
- Orchard Healthcare Research Inc.- Skokie, Skokie
ReclutandoFase 1/2
Edades de 18 en adelante · Todos los sexos · Actualizado el 5 nov 2026 · NCT06324357Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer
- Northwestern University, Chicago
Reclutando
Edades de 18 en adelante · Todos los sexos · Actualizado el 5 nov 2026 · NCT07214532Study of ORIC-114 in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration
- Northwestern University, Chicago
ReclutandoFase 1/2
Edades de 18 en adelante · Todos los sexos · Actualizado el 5 nov 2026 · NCT05315700Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
- Rush University Medical Center, Chicago
- Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 5 nov 2026 · NCT06982521A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
- City of Hope, Chicago, Chicago
- Northwestern Memorial Hospital, Chicago
- University of Illinois at Chicago, Chicago
- y 3 más
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 4 nov 2026 · NCT07174336A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
- Cancer Care Specialists of Central Illinois, O'Fallon
- Springfield Clinic, Springfield
- Carle Cancer Center, Urbana
- y 1 más
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 4 nov 2026 · NCT06790693E-Mindfulness Approaches for Living After Breast Cancer
- Northwest Community Hospital, Arlington Heights
- Advocate Outpatient Center - Aurora, Aurora
- Advocate Good Shepherd Hospital, Barrington
- y 55 más
ReclutandoFase 3
Edades de 18 a 50 · Todos los sexos · Actualizado el 4 nov 2026 · NCT06748222A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer
- City of Hope, Chicago, Chicago
ReclutandoFase 2
Edades de 18 en adelante · Mujeres · Actualizado el 4 nov 2026 · NCT07287098Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- OSF Saint Anthony's Health Center, Alton
- Advocate Outpatient Center - Aurora, Aurora
- Advocate Good Shepherd Hospital, Barrington
- y 52 más
ReclutandoEstudio observacionalSe aceptan voluntarios sanos
Edades de 40 a 75 · Todos los sexos · Actualizado el 4 nov 2026 · NCT05334069Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
- OSF Saint Anthony's Health Center, Alton
- Rush-Copley Medical Center, Aurora
- Advocate Outpatient Center - Aurora, Aurora
- y 45 más
ReclutandoEstudio observacional
Edades de 18 en adelante · Todos los sexos · Actualizado el 4 nov 2026 · NCT06418204Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
- OSF Saint Anthony's Health Center, Alton
- Advocate Outpatient Center - Aurora, Aurora
- Advocate Good Shepherd Hospital, Barrington
- y 83 más
ReclutandoFase 3
Edades de 18 a 60 · Mujeres · Actualizado el 4 nov 2026 · NCT05879926ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer
- Cancer Care Specialists, Decatur
- Cancer Care Specialists of Illinois, O'Fallon
- Carle Foundation Hospital d/b/a Carle Cancer Center, Urbana
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 30 oct 2026 · NCT07173751Real World Treatment Experience of Patients With Breast, Lung, Ovarian, Multiple Myeloma, or Acute Myelogenous Leukemia Using Remote Symptom Monitoring
- Northshore University Health System, Evanston
ReclutandoEstudio observacional
Edades de 18 en adelante · Todos los sexos · Actualizado el 30 oct 2026 · NCT05974150A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer
- The University of Chicago Medical Center, Chicago
ReclutandoFase 2
Edades de 18 en adelante · Todos los sexos · Actualizado el 29 oct 2026 · NCT07102381A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations
- City of Hope, Chicago, Zion
ReclutandoFase 1/2
Edades de 18 en adelante · Todos los sexos · Actualizado el 28 oct 2026 · NCT07109726EXActDNA-003 / NSABP B-64: Study of Molecular Residual Disease Detection in Breast Cancer (MRD)
- Rush Cancer Center, Chicago
ReclutandoEstudio observacional
Edades de 18 en adelante · Todos los sexos · Actualizado el 27 oct 2026 · NCT06401421A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
- University of Illinois Cancer Center, Chicago
ReclutandoFase 2
Edades de 18 en adelante · Todos los sexos · Actualizado el 26 oct 2026 · NCT06172478A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer
- City of Hope® Cancer Center Chicago, Zion
ReclutandoFase 1/2
Edades de 18 en adelante · Todos los sexos · Actualizado el 26 oct 2026 · NCT07100106Study to Assess the Ability of the Portable Scalp Cooling System (PSCS) to Prevent Hair Loss
- Carle Health, Urbana
Reclutando
Edades de 21 en adelante · Mujeres · Actualizado el 22 oct 2026 · NCT05484973A Phase IIIb Study to Evaluate Camizestrant Plus Ribociclib in ER-positive, HER2-negative Advanced Breast Cancer
- Research Site, Evanston
ReclutandoFase 3
Edades de 18 a 130 · Todos los sexos · Actualizado el 19 oct 2026 · NCT07647328A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
- Endeavor Health Cancer Institute at Swedish Hospital, Nancy W. Knowles Cancer Center, Elmhurst
- Prime Saint Francis-Infusion Services Evanston, Evanston
- Hope and Healing Clinical Research LLC, Hinsdale
- y 8 más
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 19 oct 2026 · NCT07062965Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
- University of Illinois Cancer Center, Chicago
- University of Chicago Medicine, Chicago
- City of Hope - Chicago, Zion
ReclutandoFase 1
Edades de 18 en adelante · Todos los sexos · Actualizado el 13 oct 2026 · NCT06293898A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)
- Rush University Medical Center ( Site 0079), Chicago
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 13 oct 2026 · NCT06312176Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer
- Carle Cancer Center, Urbana
ReclutandoFase 1/2
Edades de 18 en adelante · Todos los sexos · Actualizado el 9 oct 2026 · NCT05386108Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies
- Research Site, Chicago
ReclutandoFase 1/2
Edades de 18 a 130 · Todos los sexos · Actualizado el 5 oct 2026 · NCT05417594A Study of PHST001 in Advanced Solid Tumors
- University of Chicago Medical Center, Chicago
ReclutandoFase 1
Edades de 18 en adelante · Todos los sexos · Actualizado el 5 oct 2026 · NCT06840886A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer
- University of Illinois Cancer Center, Chicago
- The University of Chicago, Chicago
ReclutandoFase 2
Edades de 18 en adelante · Todos los sexos · Actualizado el 1 oct 2026 · NCT06369285PRE-ISPY Phase I/II Oncology Platform Program
- The University of Chicago Medicine Comprehensive Cancer Center, Chicago
- UChicago Medicine Comprehensive Cancer Center at Silver Cross Hospital, New Lenox
- UChicago Medicine Orland Park, Orland Park
ReclutandoFase 1/2
Edades de 18 en adelante · Todos los sexos · Actualizado el 30 sept 2026 · NCT05868226Phase II Protocol of Proton Therapy for Partial Breast Irradiation in Early Stage Breast Cancer
- Northwestern Medicine Chicago Proton Center, Warrenville
ReclutandoFase 2
Edades de 50 en adelante · Mujeres · Actualizado el 29 sept 2026 · NCT01766297Study to Understand Relationship Between Gut Health and Toxicities of Hormonal Breast Cancer Treatment
- The University of Chicago Medicine Comprehensive Cancer Center, Chicago
Reclutando
Edades de 18 en adelante · Todos los sexos · Actualizado el 28 sept 2026 · NCT07553234A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)
- Research Site, Chicago
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 25 sept 2026 · NCT06103864De ClinicalTrials.gov, datos obtenidos el 15 nov 2026. Cada estudio establece sus propios criterios de elegibilidad; el equipo del estudio decide quién puede participar.